A number of factors such as the soaring elderly population, surging incidence of hepatitis, and increasing investments being made in research on hepatitis and drug discovery are expected to support the hepatitis drugs market growth in the forthcoming years. Hepatitis refers to an inflammatory condition of the liver which is usually caused by a viral infection. In recent years, the rising number of partnerships and collaborations among market players has become a prominent market trend. These collaborations aim at providing new solutions for treating hepatitis.
One of the key growth drivers for the hepatitis drugs market is the rising prevalence of hepatitis B and C. According to the World Health Organization (WHO), 296 million people across the world were suffering from the chronic hepatitis B infection in 2019. Furthermore, the organization reveals that this infection affects around 1.5 million people each year. Additionally, the WHO estimates that around 58 million people are currently living with the chronic hepatitis C infection worldwide. As per the WHO estimate, 820,000 deaths and 290,000 fatalities were caused due to hepatitis B and hepatitis C, respectively, in 2019.
The type segment of the hepatitis drugs market is categorized into hepatitis A, hepatitis B, hepatitis C, and others. Among these, the hepatitis C category generated the highest revenue in the preceding years, and it is projected to demonstrate the fastest growth in the upcoming years. According to the WHO, the hepatitis C virus infection affects around 1.5 million people each year. Hepatitis C virus, a bloodborne virus, is usually transmitted through the transfusion of unscreened blood and blood components, inadequate sterilization of syringes and needles, and sharing of injection equipment for drug administration.
Thus, the surging incidence of hepatitis B and hepatitis C and increasing R&D activities in the development of hepatitis drugs will facilitate the market growth in the foreseeable future.
The global hepatitis drugs market is growing due to increasing incidences of hepatitis and increasing support from government organizations.
In addition, the growing geriatric population, and increasing R investments on hepatitis research and drug discovery are also driving the growth of the global hepatitis drugs market.Request to Get the Sample Pages at: https://www.psmarketresearch.com/market-analysis/hepatitis-drugs-market/report-sampleHowever, the high capital expenditure and stringent regulatory requirements are inhibiting the growth of the market.
The growing number of collaboration and partnerships is one of the latest trends observed in the market.Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=hepatitis-drugs-marketGeographically, North America dominated the global market of hepatitis drugs in 2014; whereas the Asian market is expected to witness the fastest growth, with a CAGR of 32.4% during the forecast period.The key companies operating in the global hepatitis drugs market include Gilead Sciences Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co. Inc., GlaxoSmithKline PLC, AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, Dynavax Technologies Corporation, and Mitsubishi Tanabe Pharma Corporation.About P IntelligenceP Intelligence is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world.
Providing the plinth of market intelligence, P as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.Contact:P IntelligenceToll-free: +1-888-778-7886 (USA/Canada) International: +1-347-960-6455Email: [email protected]: https://www.psmarketresearch.comConnect with us: LinkedIn | Twitter | Facebook
UpMarketResearch offers a latest published report on “Global Hepatitis Drugs Market Industry Analysis and Forecast 2018-2025” delivering key insights and providing a competitive advantage to clients through a detailed report.
It presents a comparative detailed analysis of all the regional and major player segments, offering readers a better knowledge of areas in which they can place their existing resources and gauging the priority of a particular region in order to boost their standing in the global market.
The numerical data is backed up by statistical tools such as SWOT analysis, BCG matrix, SCOT analysis, PESTLE analysis and so on.
The statistics are represented in graphical format for a clear understanding on facts and figures.
The generated report is firmly based on primary research, interviews with top executives, news sources and information insiders.
The major manufacturers covered in this reportHoffmann-La RocheGilead SciencesGlaxoSmithKlineJohnson & JohnsonMerckNovartisVertex PharmaceuticalsAbbvieAchillion PharmaceuticalsBristol-Myers SquibbDynavax TechnologiesMitsubishi Tanabe Pharma Geographically, this report studies the top producers and consumers, focuses on product capacity, production, value, consumption, market share and growth opportunity in these key regions, coveringNorth America (United States, Canada and Mexico)Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)Asia Pacific (China, Japan, India, Southeast Asia and Australia)Latin America (Brazil, Argentina and Colombia)Middle East and Africa On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split intoOralInjection By Application, the market can be split intoHospitalsClinicsOther The Report covers in-depth analysis as follows:Chapter 1 Overview of Hepatitis DrugsChapter 2 Global Market Status and Forecast by RegionsChapter 3 Global Market Status and Forecast by TypesChapter 4 Global Market Status and Forecast by Downstream IndustryChapter 5 North America Market Status by Countries, Type, Manufacturers and Downstream IndustryChapter 6 Europe Market Status by Countries, Type, Manufacturers and Downstream IndustryChapter 7 Asia Pacific Market Status by Countries, Type, Manufacturers and Downstream IndustryChapter 8 Latin America Market Status by Countries, Type, Manufacturers and Downstream IndustryChapter 9 Middle East and Africa Market Status by Countries, Type, Manufacturers and Downstream IndustryChapter 10 Market Driving Factor Analysis of Hepatitis DrugsChapter 11 Hepatitis Drugs Market Competition Status by Major ManufacturersChapter 12 Hepatitis Drugs Major Manufacturers Introduction and Market DataChapter 13 Upstream and Downstream Market Analysis of Hepatitis DrugsChapter 14 Cost and Gross Margin Analysis of Hepatitis DrugsChapter 15 Report ConclusionChapter 16 Research Methodology and Reference Buy this report@ https://www.upmarketresearch.com/buy/hepatitis-drugs-market “Global Hepatitis Drugs Market Industry Analysis and Forecast 2018-2025” report helps the clients to take business decisions and to understand strategies of major players in the industry.
